Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiesi Farmaceutici SPA

https://www.chiesi.com/en

Latest From Chiesi Farmaceutici SPA

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial

Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval

AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.

Policy Approvals

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.

Deals Business Strategies

Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.

Approvals Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register